Two Sigma Advisers
BOLD

Two Sigma Advisers’s Audentes Therapeutics, Inc BOLD Stock Holding History

Two Sigma Advisers’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,100
Closed -$368K – 2529
2019
Q3 		$368K Buy
13,100
+900
+7% +$30.7K ﹤0.01% 1840
2019
Q2 		$462K Buy
+12,200
New +$469K ﹤0.01% 1843
2018
Q3 		– Sell
-6,900
Closed -$264K – 2482
2018
Q2 		$264K Sell
6,900
-13,900
-67% -$515K ﹤0.01% 2135
2018
Q1 		$625K Buy
20,800
+4,300
+26% +$146K ﹤0.01% 1738
2017
Q4 		$516K Buy
+16,500
New +$453K ﹤0.01% 1763

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Two Sigma Advisers's BOLD Position: Q4 2019 in Review

Two Sigma Advisers sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 13,100 shares — an estimated $368K sold.

Two Sigma Advisers first reported a position in BOLD in Q4 2017 and held it in 5 quarters. The position peaked at $625K in Q1 2018. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Two Sigma Advisers reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Two Sigma Advisers sold 13,100 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $368K.
  • Two Sigma Advisers first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 5 quarters.
  • Two Sigma Advisers's Audentes Therapeutics, Inc position peaked at $625K in Q1 2018.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Two Sigma Advisers's 13F filing for Q4 2019, filed 14 Feb 2020.